Identification of potential HLA-A *0201 restricted CTL epitopes derived from the Epithelial Cell Adhesion Molecule (Ep-CAM) and the carcinoembryonic antigen (CEA)

Human Immunology

Volumn 53, Issue 1, 1997, Pages 81-89

  Ras, Elisabeth ^a   Van Der Burg, Sjoerd H ^a   Zegveld, Suzanne T ^a   Brandt, Remco M P ^a   Kuppen, Peter J K ^a   Offringa, Rienk ^a   Warnarr, Sven O ^a   Van De Velde, Cornelis J H ^a   Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FIBRONECTIN; HLA A ANTIGEN;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOGENICITY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULES; CELL LINE; CELL LINE, TRANSFORMED; EPITOPE MAPPING; EPITOPES; HLA-A2 ANTIGEN; HUMANS; JURKAT CELLS; MICE; MICE, TRANSGENIC; PEPTIDES; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 0030946527     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(97)00032-3     Document Type: Article

References (39)

1. Litvinov SL, Velders MP, Bakker HAM, Fleuren GJ, Warnaar SO: Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125:437, 1994.
2. Herlyn M, Steplewski Z, Herlyn D, Koprowski H: Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76:1438, 1979.
3. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P: Colorectal carcinoma antigens detected by hybridoma antibodies. Som Cell Gen 5:957, 1979.
4. Gold P, Freedman SO: Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121:439, 1965.
5. r 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res 46:1306, 1986.
6. r 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 47:2883, 1987.
7. Thompson JA, Grunert F, Zimmerman W: Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 5:344, 1991.
8. 1 C colorectal carcinoma. Lancet 343:1177, 1994.
9. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87:982, 1995.
10. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643, 1991.
11. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489, 1993.
12. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921, 1994.
13. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3515, 1994.
14. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema G, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458, 1994.
15. Coulie P, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora J-P, Renauld J-C, Boon T: A new gene coding for a differntiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180:35, 1994.
16. Disis ML, Smith HW, Murphy AE, Chen W, Cheever MA: In vitro generation of human CTL specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54:1071, 1994.
17. van Elsas A, Nijman HW, van der Minne CE, Mourer JS, Kast WM, Melief CJM, Schrier PI: Induction and characterization of CTL recognizing a mutated p21 ras peptide presented by HLA-A*0201. Int J Cancer 61:389, 1995.
18. + T cell responses. Eur J Immunol 26:435, 1996.
19. Houbiers JGA, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJM, Brand A, Momburg F, Kast WM, Melief CJM: In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53. Eur J Immunol 23:2072, 1993.
20. BCR-ABL protein by human T cells. Leukemia 9:1344, 1995.
21. Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, De Jongh BM, Drijfhout JW, ter Schegget J, Melief CJM, Kast WM: Vaccination with a cytotoxic T lymphocyte-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242, 1993.
22. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, DeLeo AB, Lotze MT: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1:1297, 1995.
23. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183:1357, 1996.
24. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojibori T: Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In Tsuji K, Aizawa M, Sasazuki T (eds): HLA 1991, proceedings of the eleventh international histocompatibility workshop and conference. Tokyo, Oxford University Press, 1992.
25. van der Burg SH, Visseren MJW, Brandt RMP, Kast WM, Melief CJM: Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 156:3308, 1996.
26. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW: Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I Major Histocompatibilicy Complex. J Exp Med 173:1007, 1991.
27. Bakker ABH, van der Burg SH, Huijbens RJF, Drijfhout JW, Melief CJM, Adema GJ, Figdor CG: Analogues of CTL epitopes with improved MHC class 1-binding affinity elicit anti-melanoma CTL recognizing the wild type epitope. Int J Cancer (in press).
28. van der Burg SH, Ras E, Drijfhout JW, Benckhuijsen WE, Bremers AJA, Melief CJM, Kast WM: An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol 44:189, 1995.
29. Nijman HW, Houbiers JGA, Vierboom MPM, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJM, Kast WM: Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 23:1215, 1993.
30. Millich DR, Hughes JL, McLachlan A, Thornton GB, Monarty A: Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc Natl Acad Sci USA 85:1610, 1988.
31. Linnenbach AJ, Wojcierowski J, Wu S, Pyrc JJ, Ross AH, Dietzhold B, Speicher D, Koprowski H: Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733. Proc Natl Acad Sci USA 86:27, 1989.
32. Drijfhout JW, Brandt RMP, D'Amaro J, Kast WM, Melief CJM: Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay. Human Immunol 43:1, 1995.
33. Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJM, Kast WM: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154:5934, 1995.
34. Oikawa S, Nakazato H, Kosaki G: Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence. BBRC 142:511, 1987.
35. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P, Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337, 1994.
36. Melief CJM, Offringa R, Toes REM, Kast WM: Peptide-based cancer vaccines Curr Opinion Immunol 8:651, 1996.
37. van Elsas A, van der Burg SH, van der Minne CE, Borghi M, Mourer JS, Melief CJM, Schrier PI: Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur J Immunol 26:1683, 1996.
38. Wentwotth PA, Vitiello A, Sidney J, Keogh E, Chesnut RW, Grey H, Sette A: Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur J Immunol 26:97, 1996.
39. Bergsagel PL, Victor-Kobrin C, Timblin CR, Trepel J, Kuehl WM: A murine cDNA encodes a pan-epithelial glycoprotein that is also expressed on plasma cells. J Immunol 148:590, 1992.